ArticleImmune network2025
Anti-arthritis Effect of Anti-chitinase-3-like 1 Antibody Through Inhibition of MMP3.
Article in Immune network, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression.Medicinal research reviews · 2026Review
- The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases.EBioMedicine · 2026Article
- Bioinformatics analysis of potential molecular markers and immunological characteristics shared between post-treatment Lyme disease syndrome and rheumatoid arthritis.Frontiers in immunology · 2026Article
- Chitinase-3-Like Protein 1 as a Therapeutic Target for Inflammatory Diseases.Biomolecules & therapeutics · 2025Review
- Evaluation of Efficacy of Water-Soluble Fraction ofAntioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitinase-3-like 1 (CHI3L1) is a key factor in regulating inflammatory processes and development of rheumatoid arthritis (RA) since is highly produced by synoviocytes and macrophages in the development RA. Collagen-induced arthritis (CIA) model is the most widely used because its pathogenesis is similar to human RA. Thus, we aimed to investigate if anti-CHI3L1 antibody could reduce RA development in the CIA model. To induce CIA, DBA1/J mice were immunized with a type II bovine collagen emulsion in complete Freund's adjuvant, and boosted type II bovine collagen. THP-1 and MH7A cells were used for pro-inflammation responses. Anti-CHI3L1 Ab treatment reduced the RA clinical score and paw thickness of mice. Inflammation-induced matrix metalloproteinase 3 (MMP3) expression was reduced by inhibiting CHI3L1, and MMP3 knockdown suppressed the expression of RA-related inflammatory cytokines in LPS-treated THP-1 and MH7A cells. Our findings suggest that anti-CHI3L1 Ab showed significant anti-arthritic effects by inhibiting MMP3 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.